Vaxcyte's Elvia Cowan sells 19,000 shares

The same-day sale was made under a Rule 10b5-1 plan adopted December 8, 2025.

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) SVP, Finance & CAO Elvia Cowan exercised a fully vested and exercisable stock option for 19,000 shares on October 5, 2026, at a $25.92 exercise price, acquiring 19,000 common shares. She sold 19,000 shares that day at $86.74 per share pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. Following the exercise, Cowan reported 74,068 shares subject to stock options.

Insider Trade Summary 10b5-1

Exercise and Sale: 19,000 shares ($1.16M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Cowan Elvia

Role SVP, Finance & CAO

Sold 19,000 shs ($1.65M)

Approx. gross sale proceeds $1.65M

Approx. exercise cost $492K

Approx. pre-tax spread $1.16M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F2	19,000	$0.00	$0.00
Exercise	Common Stock	19,000	$25.92	$492K
Sale	Common Stock F1	19,000	$86.74	$1.65M

Holdings After Transaction: Stock Option (right to buy) — 74,068 contracts (Direct); Common Stock — 27,860 shares (Direct)

Footnotes (2)

1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.
2. F2. Stock Option is fully vested and exercisable.

Key Figures

Shares exercised under stock option: 19,000 shares Exercise price: $25.92 per share Common shares acquired: 19,000 shares +3 more

6 metrics

Shares exercised under stock option 19,000 shares October 5, 2026

Exercise price $25.92 per share Stock option exercised October 5, 2026

Common shares acquired 19,000 shares October 5, 2026

Common shares sold 19,000 shares October 5, 2026

Sale price $86.74 per share Sale on October 5, 2026

Shares subject to stock options after transaction 74,068 shares Following the October 5, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, Stock Option (right to buy), fully vested and exercisable

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (right to buy) financial

"Stock Option (right to buy)"

fully vested and exercisable financial

"Stock Option is fully vested and exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PCVX shares did Elvia Cowan sell, and at what price?

Elvia Cowan sold 19,000 common shares at $86.74 per share on October 5, 2026. She exercised a fully vested option for 19,000 shares at $25.92 per share that day. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.

When does Elvia Cowan’s exercised PCVX stock option expire?

The stock option expires on August 8, 2032.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 04:08 PM Accepted by SEC EDGAR 10/07/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cowan Elvia

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance & CAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/05/2026		M		19,000	A	$25.92	46,860	D
Common Stock	10/05/2026		S(1)		19,000	D	$86.74	27,860	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$25.92	10/05/2026		M			19,000	(2)	08/08/2032	Common Stock	19,000	$0	74,068	D

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.

2. Stock Option is fully vested and exercisable.

Remarks:

	Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)